Upanib30 mg

Upanib is a Janus kinase (JAK) inhibitor approved for the treatment of several chronic inflammatory and autoimmune conditions. Its indications are classified below by strength of evidence.

Established / FDA-approved indications

• Moderately to severely active rheumatoid arthritis (RA) in adults with an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers, usually used in combination with or following methotrexate/other conventional DMARDs.
• Active psoriatic arthritis (PsA) in adults with inadequate response or intolerance to one or more TNF blockers.
• Active ankylosing spondylitis (AS) in adults with inadequate response or intolerance to TNF blockers.
• Active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, in adults with inadequate response or intolerance to TNF blockers.
• Moderately to severely active ulcerative colitis (UC) in adults with inadequate response, loss of response, or intolerance to one or more TNF blockers.
• Moderately to severely active Crohn's disease (CD) in adults with inadequate response, loss of response, or intolerance to one or more TNF blockers.
• Refractory, moderate to severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with other systemic therapies, including biologics, or when those therapies are not advisable.

Important limitation

Upanib is generally reserved for patients who have already tried and had an inadequate response to a TNF blocker; it is not recommended in combination with biologic DMARDs, other JAK inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine.

Each extended-release tablet of Upadacitinib contains Upadacitinib (as hemihydrate) in strengths of 15 mg, 30 mg, or 45 mg, along with pharmaceutically inert excipients that form the extended-release matrix. A pediatric oral solution formulation of Upadacitinib is also available in some markets.

Upanib is a selective, reversible, oral Janus kinase (JAK) inhibitor with preferential activity against JAK1 over JAK2, JAK3, and TYK2. It belongs to a class of targeted synthetic disease-modifying agents used to treat chronic inflammatory and autoimmune diseases. Upanib is formulated as an extended-release tablet taken once daily and is used when conventional or biologic therapies have not provided adequate disease control.

Upanib belongs to the therapeutic class of Janus Kinase (JAK) inhibitors, a subgroup of targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) and immunomodulators used in rheumatology, gastroenterology, and dermatology.

Mechanism of Action

Upadacitinib works by selectively and reversibly inhibiting Janus kinase 1 (JAK1), with less activity against JAK2, JAK3, and TYK2. JAK enzymes transmit signals from cytokine and growth factor receptors on the cell surface through phosphorylation of signal transducers and activators of transcription (STATs). By blocking JAK1-mediated signaling, Upadacitinib reduces the activation and function of multiple pro-inflammatory cytokines (such as IL-6, IL-7, IL-15, IL-21, interferons, and GM-CSF) that drive the inflammatory processes seen in rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, inflammatory bowel disease, and atopic dermatitis.

Pharmacokinetics

Upadacitinib is rapidly absorbed after oral administration, with peak plasma concentration reached within about 2-4 hours for the extended-release formulation. It is metabolized primarily via CYP3A4 (with minor contribution from CYP2D6) and eliminated with an effective half-life of approximately 8-14 hours, supporting once-daily dosing. Elimination occurs via both renal and hepatic/fecal routes.

Upanib extended-release tablets should be swallowed whole with a glass of water, with or without food, at about the same time each day. Do not crush, split, or chew the tablet, as this destroys the extended-release mechanism. Do not stop or change the dose of Upanib without consulting the prescribing physician.

Upanib is metabolized mainly by the CYP3A4 enzyme, making it susceptible to clinically significant drug interactions.

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir): increase Upanib blood levels and the risk of adverse effects; dose adjustment or closer monitoring is required depending on indication.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoir/phenytoin, St. John's Wort): reduce Upanib plasma levels and may decrease its therapeutic effect; co-administration is generally not recommended.
• Other immunosuppressants/biologic DMARDs/other JAK inhibitors: concurrent use with Upanib increases the risk of additive immunosuppression and serious infection, and is not recommended.
• Live vaccines: should be avoided during treatment with Upanib due to the risk of disseminated infection from the vaccine strain (see Precautions).
• Grapefruit and grapefruit juice: can raise Upanib concentrations through CYP3A4 inhibition and should be avoided.

Common side effects

• Upper respiratory tract infections
• Nausea
• Cough
• Headache
• Fever (pyrexia)
• Acne
• Herpes zoster (shingles) and herpes simplex reactivation
• Elevated blood cholesterol/lipids
• Elevated liver enzymes

Less common but serious side effects

• Serious infections, including tuberculosis reactivation and opportunistic infections
• Low neutrophil, lymphocyte, or red blood cell counts (neutropenia, lymphopenia, anemia)
• Venous and arterial thrombosis (deep vein thrombosis, pulmonary embolism)
• Major adverse cardiovascular events (heart attack, stroke)
• Malignancies, including lymphoma and lung cancer
• Gastrointestinal perforation (particularly in ulcerative colitis patients with diverticular disease)
• Serious hypersensitivity reactions (including anaphylaxis)

Patients should seek prompt medical attention for signs of infection, unusual bleeding/swelling in a limb, chest pain, shortness of breath, or sudden severe abdominal pain while taking Upanib.

Pregnancy

Upanib should be avoided during pregnancy. Animal studies have shown evidence of embryo-fetal toxicity and malformations at clinically relevant exposures, and adequate human data are lacking. Pregnancy status should be verified before starting treatment, and women of reproductive potential should use effective contraception during treatment with Upanib and for at least 4 weeks after the final dose. Upanib should be used in pregnancy only if clearly needed and the potential benefit is judged by a physician to outweigh the potential risk to the fetus.

Lactation

Upanib passes into breast milk in animal studies, and breastfeeding is not recommended during treatment and for at least 6 days after the final dose. A physician should be consulted to weigh the benefits of breastfeeding against the mother's need for treatment.

Boxed Warning (Class Warning for JAK Inhibitors)

Upanib carries a boxed warning for: serious infections (including tuberculosis reactivation, invasive fungal, and other opportunistic infections); increased risk of all-cause mortality including sudden cardiovascular death (observed with another JAK inhibitor in an RA cardiovascular outcomes trial); malignancies including lymphoma; major adverse cardiovascular events (MACE); and thrombosis (deep vein thrombosis, pulmonary embolism, arterial thrombosis). These risks are increased in patients over 50 years of age with at least one cardiovascular risk factor, and require careful individual risk-benefit assessment before and during therapy.

Key precautions

• Infection screening: Screen for latent tuberculosis and viral hepatitis (B and C) before starting Upanib; treat latent TB before initiation. Interrupt therapy if a serious infection develops.
• Live vaccines: Avoid live/live-attenuated vaccines shortly before and during treatment with Upanib.
• Laboratory monitoring: Monitor complete blood count, liver enzymes, and lipid profile periodically; interrupt treatment for significant neutropenia, lymphopenia, anemia, or suspected drug-induced liver injury.
• GI perforation risk: Use with caution in patients with diverticular disease, particularly those with ulcerative colitis; evaluate promptly for new-onset abdominal pain.
• Renal/hepatic impairment: Dose adjustment may be needed in severe renal impairment for IBD indications; avoid in severe hepatic impairment (Child-Pugh C) and end-stage renal disease.
• Elderly patients: Higher rates of serious infection and malignancy have been observed in patients 65 years and older; use the lowest effective dose.

There is limited clinical experience with Upanib overdose. In case of a suspected overdose of Upanib, seek immediate medical attention or contact a poison control center/emergency services right away. Management should be supportive, monitoring the patient for signs and symptoms of adverse reactions such as infection, unusual bleeding, or cardiovascular symptoms, with appropriate symptomatic treatment as directed by medical professionals. Do not attempt to manage a suspected overdose at home.

Store Upanib at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use

Upanib is approved for atopic dermatitis in patients 12 years and older weighing at least 40 kg; safety and efficacy for other indications (RA, PsA, AS, nr-axSpA, UC, CD) have not been established in pediatric patients.

Elderly (65 years and older)

No difference in efficacy has been observed, but elderly patients, especially those with cardiovascular risk factors, have higher observed rates of serious infection, malignancy, and major cardiovascular events with Upanib; use with caution and at the lowest effective dose (see Precautions and Warnings, Boxed Warning).

Renal impairment

No adjustment needed for mild-to-moderate impairment in RA/PsA/AS/nr-axSpA; dose reduction may apply for IBD indications in severe impairment; avoid in end-stage renal disease.

Hepatic impairment

No adjustment needed in mild-to-moderate impairment; Upanib is not recommended in severe hepatic impairment (Child-Pugh C).

Pregnancy and lactation

See Pregnancy and Lactation section above.

Duration of treatment with Upanib depends on the indication and clinical response, and is determined by the treating physician. For inflammatory bowel disease, higher induction dosing is generally limited to 8 weeks (ulcerative colitis) or 12 weeks (Crohn's disease), followed by long-term maintenance dosing if a response is achieved. For rheumatologic and dermatologic indications, treatment with Upanib is typically continued long-term as a chronic disease-modifying therapy, with periodic reassessment of ongoing need, response, and safety monitoring.

Upadacitinib belongs to the Janus Kinase (JAK) inhibitor class, specifically a JAK1-preferential inhibitor, within the broader category of targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs)/immunomodulators.

Upadacitinib selectively and reversibly inhibits Janus kinase 1 (JAK1), blocking downstream phosphorylation of STAT proteins that mediate signaling from multiple pro-inflammatory cytokines. This interrupts the intracellular signaling cascade responsible for chronic inflammation in autoimmune and inflammatory diseases, reducing immune cell activation, inflammatory mediator production, and tissue damage.

Upanib is approved for use in pediatric patients 12 years of age and older (weighing at least 40 kg) specifically for refractory, moderate-to-severe atopic dermatitis that is not adequately controlled by other systemic therapies. Safety and efficacy of Upanib in children under 12 years of age, and for any indication other than atopic dermatitis in adolescents, have not been established, and its use in these settings is not recommended outside specialist supervision. Pediatric patients on Upanib require the same infection screening, vaccination review, and laboratory monitoring recommended for adults.